AbCellera Biologics Inc [ABCL] stock is trading at $4.57, down -4.19%. An important factor to consider is whether the stock is rising or falling in short-term value. The ABCL shares have gain 6.78% over the last week, with a monthly amount drifted -2.14%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, The Benchmark Company downgraded its rating to Hold on August 20, 2024. On February 22, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $9 on the stock. KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and suggested a price target of $6 on December 05, 2023. The Benchmark Company downgraded its rating to a Hold. In a note dated February 28, 2023, Cowen initiated an Outperform rating.
AbCellera Biologics Inc [ABCL] stock has fluctuated between $1.89 and $5.82 over the past year. Currently, Wall Street analysts expect the stock to reach $20.17 within the next 12 months. AbCellera Biologics Inc [NASDAQ: ABCL] shares were valued at $4.57 at the most recent close of the market. An investor can expect a potential return of 341.36% based on the average ABCL price forecast.
Analyzing the ABCL fundamentals
AbCellera Biologics Inc [NASDAQ:ABCL] reported sales of 32.88M for the trailing twelve months, which represents a growth of 133.29%. Gross Profit Margin for this corporation currently stands at -1.88% with Operating Profit Margin at -9.77%, Pretax Profit Margin comes in at -6.05%, and Net Profit Margin reading is -5.04%. To continue investigating profitability, this company’s Return on Assets is posted at -0.12, Equity is -0.16 and Total Capital is -0.24. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, AbCellera Biologics Inc’s Current Ratio is 11.07. On the other hand, the Quick Ratio is 11.07, and the Cash Ratio is 1.38. Considering the valuation of this stock, the price to sales ratio is 41.53, the price to book ratio is 1.36.
